In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Myocardial constructive work is additive to left ventricular dyssynchrony and volumetric response to CRT in the prediction of overall mortality after CRT implantation.

Session Poster Session 1

Speaker Elena Galli

Congress : ESC Congress 2018

  • Topic : heart failure
  • Sub-topic : Heart Failure with Reduced Ejection Fraction
  • Session type : Poster Session
  • FP Number : P893

Authors : E Galli (Rennes,FR), A Hubert (Rennes,FR), V Le Rolle (Rennes,FR), A Hernandez (Rennes,FR), O Smiseth (Oslo,NO), C Leclercq (Rennes,FR), E Donal (Rennes,FR)

E. Galli1 , A. Hubert1 , V. Le Rolle2 , A. Hernandez2 , O. Smiseth3 , C. Leclercq1 , E. Donal1 , 1University Hospital of Rennes, Cardiology - Rennes - France , 2University of Rennes, Laboratoire Traitement du Signal et de l'Image, INSERM U-1099 - Rennes - France , 3University of Oslo - Oslo - Norway ,

European Heart Journal ( 2018 ) 39 ( Supplement ), 169

Background: Recent studies have shown that myocardial constructive work (CW) assessed by pressure strain loops (PSLs) is an independent predictor of the response to cardiac resynchronization therapy (CRT). Aim of our study is to assess if CW has an additive value in the prediction of long-term outcome of patients undergoing CRT, in addition to CRT response (CRT+) and left ventricular (LV) dyssynchrony.

Methods: 2D standard and speckle tracking echocardiography were performed in 166 CRT candidates (mean age: 66±10 years, males: 69%, QRS duration: 165±19 ms) before CRT implantation and at 6-month follow-up. Myocardial constructive work (CW) was assessed by PSLs. CRT+ was defined by a >15% reduction in left-ventricular end-systolic volume at 6-month follow-up and was observed in 48 (29%) patients. LV dyssynchrony was visually assessed by septal flash.

Results: After a median FU of 4 years (range: 1.3–5 years), all-cause death occurred in 28 patients (17%). At multivariable Cox-regression analysis, CW and age were the only prognostic predictors of cardiac death (Table 1). At ROC curve analysis, CW≤888 mmHg% was the best cut-off to predict all-cause mortality (AUC 0.67, p=0.004). Variables with a p-value <0.05 at univariable Cox-regression analysis were used to test the prognostic power of different nested models. Only the addition of CW≤888 mmHg% to a model including clinical variables (age and ischemic etiology for heart failure), SF, and CRT+ caused a significantly increase in model power for the prediction of prognosis cardiac (χ2: 13.2 vs 28.1, p=0.004) (Figure 1).

Conclusions: The estimation of myocardial CW has an additive value for the prediction of mortality in CRT candidates, over SF and volumetric CRT-response.

Table 1
Cardiac deathUnivariable analysisMultivariable analysis
HR95% CIp-valueHR95% CIp-value
Age, per year1.08(1.01–1.15)0.021.07(1.00–1.15)0.04
Ischaemic disease3.99(1.34–11.94)0.012.33(0.71–1.15)0.16
NYHA >21.39(0.46–4.24)0.56
LVEF, per %0.99(0.92–1.08)0.89
Septal flash0.19(0.06–0.62)0.0060.48(0.12–1.95)0.30
CW, per mmHg%0.99(0.99–1.00)0.040.99(0.99–1.00)0.04
Figure 1

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are